HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leiner Chapter 11 Plan To Include New Capital, Credit, Debt Restructuring

This article was originally published in The Tan Sheet

Executive Summary

Leiner Health Products will use a tentative $20 mil. equity investment to support ongoing operations as it prepares to seek Chapter 11 protection in early 2002, the company stated

You may also be interested in...



Leiner Ownership Expected To Change Hands In Recapitalization Deal

North Castle Partners is reportedly in the second round of talks to sell its stake in Leiner Health Products to another private equity firm

Leiner $30 Mil. Vitamin Price-Fixing Settlement Applied To Outstanding Debt

Leiner Health Products' recent settlement in the federal vitamin price-fixing litigation has reduced the company's outstanding indebtedness by more than $30 mil

Leiner’s new CFO

Former Weider CFO & Chief Operating Officer Robert Reynolds to replace David Coles, who took over as interim CFO in September, private labeler says Jan. 28. Coles works with Alvarez & Marsal, a turnaround specialist firm, and will continue to oversee Leiner's restructuring, slated for completion in approximately two-and-a-half months. Reynolds was with Weider from 1990-1999 and most recently was CEO of Luxul Corp., a wireless broadband communications company he co-founded. Leiner also says it has begun soliciting approval from senior bank lenders and bondholders for its Chapter 11 restructuring package (1"The Tan Sheet" Nov. 12, 2001, p. 11)...

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS131601

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel